Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [31] A Case of Metastatic HER2-Amplified Non-Small-Cell Lung Cancer (NSCLC) Treated with Trastuzumab Deruxtecan
    Yun, K.
    Bazhenova, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E38 - E38
  • [32] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
  • [33] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
    Nagasaka, Misako
    Singh, Vijendra
    Baca, Yasmine
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Uprety, Dipesh
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Oberley, Matthew
    Feldman, Rebecca
    Xiu, Joanne
    Korn, W. Michael
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
  • [34] Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
    Ahn, Beung-Chul
    Han, Ye-Jeong
    Kim, Hye Ryun
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    CANCER RESEARCH AND TREATMENT, 2023, 55 (02): : 488 - 497
  • [35] Trastuzumab in the treatment of non-small cell lung cancer
    Azzoli, CG
    Krug, LM
    Miller, VA
    Kris, MG
    Mass, R
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 59 - 65
  • [36] Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report
    He, Xincheng
    Hou, Lei
    Bai, Jun
    Sun, Chao
    Wang, Dongjie
    An, Gaili
    ANTI-CANCER DRUGS, 2024, 35 (01) : 101 - 108
  • [37] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
    Smit, E. F.
    Felip, E.
    Uprety, D.
    Nakagawa, K.
    Paz-Ares, L.
    Pacheco, J.
    Li, B. T.
    Planchard, D.
    Baik, C.
    Goto, Y.
    Murakami, H.
    Saltos, A.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Yan, Q.
    Feng, W.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
  • [38] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
    Hotta, Katsuyuki
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Ichihara, Eiki
    Kubo, Toshio
    Ninomiya, Takashi
    Chikamori, Kenichi
    Harada, Daijiro
    Nogami, Naoyuki
    Hirata, Taizo
    Hinotsu, Shiro
    Toyooka, Shinichi
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 273 - 279
  • [39] The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer
    Xia, Yang
    Huang, Xiu
    Jin, Rui
    Li, Wen
    Shen, Huahao
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [40] FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
    Mehta, Gautam U.
    Vellanki, Paz J.
    Ren, Yi
    Amatya, Anup K.
    Mishra-Kalyani, Pallavi S.
    Pan, Lili
    Zirkelbach, Jeanne F.
    Pan, Yuzhuo
    Liu, Jiang
    Aungst, Stephanie L.
    Miller, Claudia P.
    Shah, Mirat
    Rahman, Nam Atiqur
    Theoret, Marc
    Kluetz, Paul
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    ONCOLOGIST, 2024, 29 (08): : 667 - 671
12345